(Bloomberg) Johnson & Johnson shares tumbled after the company said profit margins in its medical device and technology unit fell last quarter and drug sales will be lower in the second half of the year than the first.Most Read from BloombergChina Weighs Stock Market Rescue Package Backed by $278 BillionNetflix Pays $5 Billion for ‘Raw’ in Bet on Live EventsAn Isolated Israel Doubles Down on War in Gaza — At All CostsIndia Tops Hong Kong as World’s Fourth-Largest Stock MarketHong Kong Stocks
Despite witnessing a late recovery in September, domestic pharma sales moderated sequentially in Q2, which is likely to put pressure on the July-September earnings of drugmakers
AI has a potentially large role to play in making sense of the data pieces. Some of the earliest widespread applications may be where the bar isn’t daunting.